Breakthrough Therapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Breakthrough Therapy stocks.

Breakthrough Therapy Stocks Recent News

Date Stock Title
Feb 8 VRTX Vertex Pharmaceuticals: Pioneering Scientific Advances To Tackle Serious Diseases
Feb 8 REGN EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
Feb 8 VRTX Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging
Feb 8 VRTX What's Going On With Vertex Pharmaceuticals (VRTX) Stock Wednesday?
Feb 8 VRTX Here's What Key Metrics Tell Us About Vertex (VRTX) Q4 Earnings
Feb 8 VRTX Vertex Pharmaceuticals (VRTX) Q4 2022 Earnings Call Transcript
Feb 8 VRTX Dow Jones Futures: Market Rallies On Powell, Microsoft AI Arms Race; Fortinet, Enphase Jump On Earnings
Feb 8 VRTX Vertex has built a CF empire. Next up: cell and gene therapy.
Feb 8 VRTX Vertex Pharmaceuticals Incorporated (VRTX) Q4 2022 Earnings Call Transcript
Feb 7 VRTX Vertex Pharmaceuticals Incorporated 2022 Q4 - Results - Earnings Call Presentation
Feb 7 VRTX Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates
Feb 7 REGN Regeneron will accelerate capital spending by at least 40%
Feb 7 VRTX Why Vertex Pharmaceuticals Stock Is Moving During Tuesday's After-Hours Session
Feb 7 VRTX Vertex indicates slowdown in growth; announces share buybacks
Feb 7 VRTX Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views
Feb 7 VRTX Vertex Pharmaceuticals Non-GAAP EPS of $3.76 beats by $0.25, revenue of $2.3B in-line
Feb 7 VRTX Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
Feb 7 VRTX Vertex under fire as activists demand generics for best-selling drug
Feb 7 VRTX Vertex Pharmaceuticals Battles Back With A Boost To 81 RS Rating
Feb 7 HUMA Presenting on the Emerging Growth Conference on February 8 Register Now
Breakthrough Therapy

Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.

Browse All Tags